This story is available exclusively to Insider subscribers. Become an Insider and start reading now. 23andMe in February said it's going public in a deal that values the company at $3.5 billion. Despite 23andMe's success, the consumer genomics market has largely bottomed out, an analyst said. Others hoping to cash in on genetic health assessments have pivoted or shuttered efforts altogether. As consumer genetics giant 23andMe prepares to go public, the personal genetics market isn't what it once was. "We've kind of hit the bottom and we're stable right now," Evercore analyst Vijay Kumar told Insider. But that hasn't stopped competitors from building out niches in other areas.